<DOC>
	<DOCNO>NCT00700102</DOCNO>
	<brief_summary>This study evaluate efficacy safety add bevacizumab crossover fluoropyrimidine-based chemotherapy patient metastatic colorectal cancer experience disease progression first line treatment standard chemotherapy plus bevacizumab . Participants receive chemotherapy alone , combination bevacizumab . The anticipated time study treatment disease progression unacceptable toxicity occur . Participants allow continue bevacizumab , even stop chemotherapy .</brief_summary>
	<brief_title>A Study Avastin ( Bevacizumab ) Plus Crossover Fluoropyrimidine-Based Chemotherapy Patients With Metastatic Colorectal Cancer .</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<criteria>Adult patient , &gt; =18 year age Metastatic colorectal cancer disease progression Previously treat firstline chemotherapy plus Avastin Eastern Cooperative Oncology Group ( ECOG ) performance status &lt; =2 . Diagnosis progression disease 3 month last Avastin administration Firstline patient progressionfree survival firstline &lt; 3 month Patients receive less 3 consecutive month Avastin firstline therapy Past current history ( within last 2 year prior treatment start ) malignancy , except curatively treat basal squamous cell cancer skin situ cancer cervix Clinically significant cardiovascular disease within 6 month prior start study treatment Known central nervous system ( CNS ) disease , except treat CNS metastasis define protocol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2015</verification_date>
</DOC>